James Quigley
Stock Analyst at Goldman Sachs
(1.27)
# 3,638
Out of 5,072 analysts
24
Total ratings
50%
Success rate
-1.39%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Maintains: Buy | $60 → $54 | $49.35 | +9.42% | 1 | Nov 28, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $130.40 | -9.51% | 2 | Sep 12, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $67.66 | +16.76% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $49.88 | +30.31% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.84 | +18.78% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $31.32 | +27.71% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.33 | +380.48% | 3 | Jun 23, 2023 |
Novo Nordisk
Nov 28, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $49.35
Upside: +9.42%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $130.40
Upside: -9.51%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $67.66
Upside: +16.76%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $49.88
Upside: +30.31%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.84
Upside: +18.78%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $31.32
Upside: +27.71%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.33
Upside: +380.48%